tirzepatide vs semaglutide trial SURPASS-2 (NEJM 2021) was the definitive head-to-head: 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions tirzepatide vs semaglutide trial efficacy

The superior performance of Tirzepatide is attributed to its unique dual-target mechanism of action: In other words, compared to Semaglutide's single-target action, Tirzepatide attacks both problems suppressing appetite and accelerating fat burning addressing both overeating and insufficient energy expenditure

Many patients wonder if spacing doses further apartlike every two weekscould work, but clinical evidence supports a seven-day dosing interval for steady appetite suppression and metabolic benefits

This can be particularly useful for patients who struggle to maintain adequate nutrition due to the reduced appetite associated with GLP-1 agonists

(verified owner) Very helpful in my weight loss journey, no side effects